NASDAQ
4.21USD
-0.15 (-3.44%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.3M
P/E
—
EPS
—
Beta
2.56
52W range
3.18-71.5
Day range
4.15–4.49
Open
4.38
Prev close
4.36
Volume
25.4K
Avg volume
2.1M
Dividend
0.00
IPO
1991-08-29
https://www.globenewswire.com/news-release/2026/07/15/3327620/0/en/Ernexa-Therapeutics-Receives-Independent-Validation-of-ERNA-101-with-Complete-Tumor-Clearance-and-Durable-Survival-in-Ovarian-Cancer-Models-Ahead-of-Planned-Clinical-Entry.html · 7/15/2026+1.00
https://www.globenewswire.com/news-release/2026/06/17/3313445/0/en/Ernexa-Therapeutics-Positioned-to-Become-a-Clinical-Stage-Biotechnology-Company-as-ERNA-101-On-Track-for-Planned-Q3-2026-IND-Submission-and-First-in-Human-Study.html · 6/17/2026+0.90
https://www.globenewswire.com/news-release/2026/06/09/3308857/0/en/Ernexa-Therapeutics-Highlights-Ovarian-Cancer-Unmet-Need-Hope-for-Patients-and-Potential-Accessibility-Advantages-of-ERNA-101-in-Virtual-Investor-KOL-Connect-Segment-Featuring-Dr-I.html · 6/9/2026+0.80
https://www.zacks.com/stock/news/2924151/erna-stock-shoots-up-140-in-a-month-here-s-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-analyst_blog|price_surge_/_plunge-2924151 · 5/20/2026+0.80
https://www.defenseworld.net/2026/03/14/ernexa-therapeutics-inc-nasdaqerna-short-interest-update.html · 3/14/2026-0.30
https://www.globenewswire.com/news-release/2026/01/06/3213604/0/en/Ernexa-Therapeutics-Announces-Successful-Pre-IND-FDA-Meeting-and-Continues-Progress-Toward-First-in-Human-Trial-in-Ovarian-Cancer.html · 1/6/2026+1.00
https://www.globenewswire.com/news-release/2025/09/17/3151618/0/en/Ernexa-Therapeutics-to-Present-New-Data-in-Oral-Presentation-at-AACR-Special-Conference-in-Cancer-Research.html · 9/17/2025+0.80
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
